Biosimilar insulins: a European perspective

J. H. DeVries; S. C. L. Gough; J. Kiljanski; L. Heinemann

doi:10.1111/dom.12410

Biosimilar insulins: a European perspective

J. H. DeVries
, S. C. L. Gough
, J. Kiljanski
, L. Heinemann

Research output: Contribution to journal › Review article › Academic › peer-review

11 Downloads (Pure)

Abstract

Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins

Original language	English
Pages (from-to)	445-451
Journal	Diabetes, obesity & metabolism
Volume	17
Issue number	5
DOIs	https://doi.org/10.1111/dom.12410
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/dom.12410

Biosimilar-insulins-a-european-perspective.pdfFinal published version, 520 KBLicence: Taverne

Cite this

@article{177e4b2a92a14d3da1a35e4efe693850,

title = "Biosimilar insulins: a European perspective",

abstract = "Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins",

author = "DeVries, \{J. H.\} and Gough, \{S. C. L.\} and J. Kiljanski and L. Heinemann",

year = "2015",

doi = "10.1111/dom.12410",

language = "English",

volume = "17",

pages = "445--451",

journal = "Diabetes, obesity \& metabolism",

issn = "1462-8902",

publisher = "Wiley Blackwell",

number = "5",

}

TY - JOUR

T1 - Biosimilar insulins: a European perspective

AU - DeVries, J. H.

AU - Gough, S. C. L.

AU - Kiljanski, J.

AU - Heinemann, L.

PY - 2015

Y1 - 2015

N2 - Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins

AB - Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins

U2 - 10.1111/dom.12410

DO - 10.1111/dom.12410

M3 - Review article

C2 - 25376600

SN - 1462-8902

VL - 17

SP - 445

EP - 451

JO - Diabetes, obesity & metabolism

JF - Diabetes, obesity & metabolism

IS - 5

ER -

Biosimilar insulins: a European perspective

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this